Maxim Group analyst Caroline Palomeque maintained a Buy rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI) today and set a price target of $9. The company’s shares closed on Tuesday at $4.12.
Palomeque wrote:
“Brainstorm received a Decision to Grant notice from the to issue a patent for NurOwn. Grant notice is the final approval and the patent is granted soon thereafter.”
According to TipRanks.com, Palomeque ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 46.5% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $10 average price target, which is a 142.7% upside from current levels. In a report issued on June 26, H.C. Wainwright also maintained a Buy rating on the stock with a $11 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.35 and a one-year low of $2.88. Currently, Brainstorm Cell Therapeutics has an average volume of 153.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
